Topotecan in chronic lymphocytic leukemia

Cancer

Volumn 75, Issue 5, 1995, Pages 1104-1108

  O'Brien, Susan ^a   Kantarjian, Hagop ^a   Ellis, Amy ^a   Zwelling, Leonard ^a   Estey, Elihu ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

chronic lymphocytic leukemia; DNA protein cross links; topoisomerase I; topotecan

Indexed keywords

ANTIEMETIC AGENT; CHLORAMBUCIL; CISPLATIN; DNA; DNA TOPOISOMERASE; DOXORUBICIN; FLUDARABINE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RASH; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CROSS-LINKING REAGENTS; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGE; TOPOTECAN; TREATMENT OUTCOME;

EID: 0028930068     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950301)75:5<1104::AID-CNCR2820750509>3.0.CO;2-B     Document Type: Article

References (16)

1. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with pre‐clinical studies
2. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880)
3. DNA topoisomerase I and II as targets for rational design of new anticancer drugs
4. Topoisomerase I inhibitors: a new class of anticancer agents
5. Resistance of human leukemic and normal lymphocytes to drug‐induced DNA cleavage and low levels of DNA topoisomerase II
6. Effect of p‐glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK & F 104864), a new camptothecin analogue
7. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thioposphoramide
8. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute sponsored working group
9. Drug‐induced DNA‐protein crosslinks in non‐radiolabeled cells: potential application to patient material [abstract]
10. Quantification of topoisomerase‐DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase‐directed agent
11. Clinical staging of chronic lymphocytic leukemia
12. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
13. Studies on camptothecin I: effects on nucleic acid and protein synthesis
14. Topoisomerase I‐targeting drugs: mechanism of inhibition and cytotoxicity
15. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony‐forming units in vitro